Astellas Pharma US, Inc announced the results of a pivotal phase 3 clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB).
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.